Grifols SA (GRFS)
9.545
+0.48
(+5.24%)
USD |
NASDAQ |
Nov 14, 16:00
9.545
0.00 (0.00%)
After-Hours: 20:00
Grifols Net Income (Quarterly): 56.85M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 56.85M |
| June 30, 2024 | 15.98M |
| December 31, 2023 | 79.19M |
| September 30, 2023 | 64.83M |
| June 30, 2023 | 41.62M |
| December 31, 2022 | 20.52M |
| September 30, 2022 | 44.89M |
| June 30, 2022 | 96.23M |
| June 30, 2021 | 164.97M |
| March 31, 2021 | 156.57M |
| December 31, 2020 | 158.41M |
| September 30, 2020 | 312.74M |
| June 30, 2020 | 35.10M |
| March 31, 2020 | 205.68M |
| December 31, 2019 | 223.40M |
| September 30, 2019 | 151.80M |
| June 30, 2019 | 193.80M |
| March 31, 2019 | 129.92M |
| December 31, 2018 | 146.44M |
| September 30, 2018 | 173.62M |
| June 30, 2018 | 209.64M |
| March 31, 2018 | 176.17M |
| December 31, 2017 | 271.95M |
| September 30, 2017 | 180.93M |
| June 30, 2017 | 158.29M |
| Date | Value |
|---|---|
| March 31, 2017 | 142.74M |
| December 31, 2016 | 150.34M |
| September 30, 2016 | 158.10M |
| June 30, 2016 | 157.26M |
| March 31, 2016 | 138.17M |
| December 31, 2015 | 142.82M |
| September 30, 2015 | 155.70M |
| June 30, 2015 | 146.99M |
| March 31, 2015 | 144.98M |
| December 31, 2014 | 163.94M |
| September 30, 2014 | 151.28M |
| June 30, 2014 | 142.45M |
| March 31, 2014 | 165.73M |
| December 31, 2013 | 106.88M |
| September 30, 2013 | 111.66M |
| June 30, 2013 | 119.90M |
| March 31, 2013 | 120.14M |
| December 31, 2012 | 76.98M |
| September 30, 2012 | 79.82M |
| June 30, 2012 | 84.70M |
| March 31, 2012 | 88.54M |
| December 31, 2011 | 8.776M |
| September 30, 2011 | 34.66M |
| June 30, 2011 | -20.71M |
| March 31, 2011 | 46.02M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
15.98M
Minimum
Jun 2024
312.74M
Maximum
Sep 2020
111.80M
Average
79.19M
Median
Dec 2023
Net Income (Quarterly) Benchmarks
| Cellectis SA | -23.06M |
| Adaptimmune Therapeutics PLC | 69.52M |
| Akari Therapeutics PLC | -7.558M |
| Biodexa Pharmaceuticals PLC | -- |
| Verona Pharma PLC | -42.96M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.972B |
| Total Expenses (Quarterly) | 1.621B |
| EPS Diluted (Quarterly) | 0.0836 |
| Enterprise Value | 8.218B |
| Gross Profit Margin (Quarterly) | 40.53% |
| Profit Margin (Quarterly) | 2.88% |
| Earnings Yield | 3.32% |
| Operating Earnings Yield | 17.54% |
| Normalized Earnings Yield | 3.643 |